Summary Bcl-2 has been demonstrated to inhibit apoptosis in breast cancer cells in vitro, and the ratio between Bcl-2 and its proapoptotic homologue Bax seems to be an important determinant of cellular sensitivity to induction of apoptosis. However, little information is available on the relationship between Bcl-2 and the rate of apoptotic and necrotic cell death in breast tumours. From a series of 441 premenopausal, lymphnode-negative breast cancer patients, a subset of 49 tumours was selected in which immunostaining for the 26-kDa isoform of Bcl-2 was either absent (n = 23) or very high (n = 26). High expression of Bcl-2 was found to be strongly associated with low rates of apoptotic (P < 0.001) and necrotic cell death (P < 0.001). The mean value of the apoptotic index was 2.69% ± 1.40% in Bcl-2-negative tumours and 0.68% ± 1.00% in Bcl-2-positive tumours. Expression of the proapoptotic protein Bax correlated neither with Bcl-2 nor with the frequency of apoptotic cells. Immunostaining for the antiapoptotic Bcl-2 homologue Bcl-XL correlated with Bcl-2 expression (P < 0.001) but not with apoptosis. High proliferation rate and high tumour grade (Bloom-Richardson) were strongly associated with absence of Bcl-2 expression (P < 0.001). p53 accumulation was associated with absence of Bcl-2 expression and increased apoptotic activity. Loss of Bcl-2 expression was strongly correlated with increased apoptotic and necrotic cell death, high proliferation rate and high tumour grade, supporting a model in which Bcl-2 not only mediates cell death, but also cell division in breast cancer tissue, and in which regulation of cell division and cell death are tightly linked.
lack of predictive value of Bcl-2 expression, which has also been found for 5-FU based chemotherapy in colorectal adenocarcinomas (Schneider et al, 1997) , is not in line with most in vitro experiments, which clearly suggest an increased resistance to chemotherapy in tumour cell lines overexpressing Assuming that increased resistance to induction of apoptosis leads to increased resistance to chemotherapy, this could imply that in breast tumours Bcl-2 has little impact on the sensitivity to induction of apoptosis. However, it may also be possible that the efficacy of Bcl-2 to inhibit apoptosis is determined in large part by interactions with other proteins, including other Bcl-2 family members, by post-translational modification, such as phosphorylation (Blagosklonny et al, 1996; Guan et al, 1996) or mutations.
If immunohistochemically detectable Bcl-2 protein is by itself capable of attenuating the rate of cell death in breast cancer cells, one may expect a strong correlation between Bcl-2 staining and the proportion of apoptotic cells and/or necrotic areas in breast cancer tissue. We wanted to test this in our series of tumours from 441 node-negative, premenopausal breast cancer patients, previously analysed for Bcl-2 immunostaining (van Slooten et al, 1996) . However, apoptosis is a difficult variable to adequately quantitate in tissue sections. With the use of terminal transferase (TdT)-mediated dUTP nick end-labelling (TUNEL) it is possible to visualize single cells or areas in a tissue containing fragmented DNA, but because of the fragmentation of the apoptotic nuclei quantitation remains difficult. Therefore, to unequivocally detect an effect of Bcl-2 expression on apoptotic activity, we determined the apoptotic index and the amount of necrosis in a preselected series of 49 breast cancers that either completely lacked or showed strong staining for Bcl-2 protein.
The results presented here show that in invasive breast cancer, loss of Bcl-2 expression is closely correlated with increased apoptotic and necrotic cell death, high proliferation rate and high tumour grade. Our findings support a model in which Bcl-2 not only mediates cell death but also cell division in breast cancer tissue and in which regulation of cell division and cell death are tightly linked.
MATERIALS AND METHODS
From a series of 441 node-negative, premenopausal breast cancer patients, previously analysed for Bcl-2 immunostaining (van Slooten et al, 1996) , a subset of 49 tumours (including 41 ductal carcinomas) was selected, in which Bcl-2 was either absent (n = 23) or strongly stained (n = 26). Apart from Bcl-2, various prognostic factors (including p53, ER, Ki-67, mitotic index) have been analysed previously (Clahsen et al, 1997) .
Immunohistochemical analysis
The expression of Bcl-2, p53, oestrogen receptor (ER) and Ki-67 was determined immunohistochemically on paraffin sections using a microwave antigen retrieval method, the monoclonal antibodies clone 124 (Bcl-2, Boehringer Mannheim, Mannheim, Germany), Do-7 (p53, Dako, Glostrup, Denmark), iD5 (ER, Dako) , mPRI (PgR Transbio, Paris, France), 3B5 (c-ErbB-2 (van de Vijver et al, 1988)), MIB-1 (Ki-67 antigen, Immunotech, Marseilles, France) and the polyclonal antibodies 3666E (Bax, PharMingen, San Diego, CA, USA), I-19 (Bax, Santa Cruz, CA, USA) and S-18 (Bcl-X, Santa Cruz).
Briefly, sections were deparaffinized in xylene, endogenous peroxidase was blocked in methanol/hydrogen peroxide 0.03% for 20 min and sections were rehydrated. Next, sections were heated in 10 mm citrate buffer pH 6.0, 100°C, for 10 min in a microwave oven and cooled down for 2 h. After washing in double-distilled water followed by phosphate-buffered saline (PBS), sections were incubated overnight with the primary antibody (clone 124, 1:100; Do-7, 1:100; lD5, 1:200; mPRI, 1:80; 3B5, 1:20000; MIB-1, 1:200; 3666E, 1:1000; 1-19, 1:400). After thorough washing in PBS, sections were incubated with biotinylated secondary antibodies (DAKO) followed by StreptABComplex (Dako). Staining was visualized using diaminobenzidine (Sigma, St Louis, MO, USA). Depending on the antibody, sections were scored either semiquantitatively (Bcl-2, p53, ER) or quantitatively (Ki-67) as described previously (Clahsen et al, 1997; van Slooten et al, 1996) . The mitotic index was determined by counting the number of mitosis per ten high-power fields in H&E sections. Staining for microvessels was done using the monoclonal antibody clone IC/70A (Dako) against CD3 1, as previously described (Clahsen et al, 1997) . Microvessel density (MVD) was determined by counting the most vascular area at low magnification (25x).
Vessels were then counted on three 250x (0.384 mm2) fields, of which the highest count was used for statistical analysis.
Detection of apoptotic cells
Apoptotic cells were visualized using terminal transferase (TdT)-mediated dUTP nick end-labelling of DNA strand breaks according to a protocol described by Gavrieli et al (1992) , using the enzyme TdT (Boehringer Mannheim) and biotinylated dUTP (Boehringer Mannheim). Optimal results were obtained by preheating tissue sections in 10 mm citrate buffer (pH 6.0, 70°C, 20 min), followed by treatment with 20 g ml-' proteinase K (Boehringer Mannheim) for 60 min at 37°C. After thorough washing in TBS (pH 7.4), sections were incubated with StreptABComplex (Dako) and the tailing reaction was visualized using diaminobenzidine (Sigma). Sections were counterstained with ethyl green. Using a Zeiss Axioscop microscope (Carl Zeiss, Oberkochen, Germany) with a checkerboard grid in the ocular, tissue sections were analysed at a magnification of 640x;
within the grid frame all tumour cells were counted. Within each section a variable number of randomly distributed areas was evaluated until at least 1000 tumour cells had been counted. Positively stained cells that also displayed an apoptotic morphology (i.e. cell shrinkage and nuclear condensation/fragmentation) were scored and expressed as a percentage of tumour cells or apoptotic index (Al). Necrotic areas were excluded from the analysis. The analysis was performed without prior knowledge of Bcl-2 expression.
The amount of necrosis in each section was scored semiquantitatively by two observers (H-JvS and MJvdV), using four categories: none, low (< 25% per field at a magnification of 100x), intermediate (25-50% per field at a magnification of 100x) and high (> 50% per field at a 100x magnification).
Statistical methods
Differences between distributions of variables among patient groups were tested for using Fischer's exact test. Correlations between continuous variables were expressed using the Wilcoxon coefficient. Median, interquartile range and minimum and maximum values were used to analyse the effects and interactions of several factors at once. The median (0.77%) was used as a cutoff value for apoptotic index, whereas for necrosis the cut-off was none vs low, intermediate and high. Bax and Bcl-XL expression were scored using the scoring system previously described for Bcl-2 (van Slooten et al, 1996) . Bax-negative tumours and Bcl-X -negative tumours were defined as those tumours with a staining score of 3 and 2 respectively. The median value of MVD was used as cut-off value (109 mm-2). The cut-off values used for the other prognostic factors were identical to the values used in previous analyses. Statistical analyses were performed using the StatExact (Cytel Software Corporation, Cambridge, MA, USA) and SPSS-software (SPSS, Chicago, IL, USA).
RESULTS
The majority of tumours in this preselected series either showed a very low or a very high rate of apoptosis. Table 1 shows the associations between Bcl-2 expression, apoptotic activity and proliferative activity. As shown, Bcl-2 expression was correlated with a low apoptotic index (Al) (P < 0.001) and low proliferative activity as determined by mitosis count and immunostaining for the Ki-67 antigen (P < 0.001). The median value of the Al was 2.67% in Bcl-2-negative tumours and 0.39 in Bcl-2-positive tumours. Figure 1 shows representative examples of Bcl-2 and TUNEL staining in Bcl-2-positive and Bcl-2-negative tumours. with Bcl-2 (P = 0.751), whereas expression of the antiapoptotic protein Bcl-XL was associated with expression of Bcl-2 (P < 0.001). However, neither Bax nor Bcl-XL expression significantly affected the mean AIs in Bcl-2-positive and Bcl-2-negative tumours respectively. As shown, we also semiquantitatively assessed the amount of necrosis. Of the tumours without necrotic areas 68.0% were Bcl-2-positive, whereas only 32.0% of the tumours with necrotic areas were Bcl-2-positive (P = 0.003). In line with their lack of correlation with the Al, neither Bax nor Bcl-XL expression correlated with necrosis.
Although this series of breast cancers had been preselected for lack of Bcl-2 expression and high Bcl-2 expression, tumour cell proliferation and tumour grade were also highly associated with apoptosis. Table 3 shows a cross-tabulation of apoptotic index and the number of mitosis, Ki-67 positivity, tumour grade and p53 status. Of the 26 tumours with 0-9 mitosis, five (19.2%) had high rates of apoptosis, whereas in 12 (92.3%) of the 13 tumours with counts greater than or equal to 20 the rate of apoptosis was high. Apoptotic and mitotic activity showed a good correlation (Wilcoxon rank test, P < 0.001). Of the 19 tumours with less than 20% Ki-67-positive cells (a measure for tumour growth fraction) two (10.5%) displayed a high rate of apoptosis, whereas 22 Figure 2 shows box plots depicting the median, interquartile range, as well as the minimum and maximum values of AIs in Bcl-2-negative and Bcl-2-positive tumours with either low and high mitotic activity (Figure 2A ) and Ki-67 positivity ( Figure 2B ) respectively. These graphs show that the median apoptotic index is consistently higher in rapidly proliferating tumours and is especially high in those rapidly proliferating tumours that do not express Bcl-2. MVD was correlated neither with Bcl-2 expression ( necrosis and apoptosis, and that both types of cell death can be partially prevented by the expression of Bcl-2 or Bcl-X, as well as by inhibitors of enzymes known to be involved in the execution of apoptosis (caspases). This suggests that apoptosis and ischaemic necrosis may share certain biochemical pathways (Shimizu et al, 1995a; 1996) .
It has been demonstrated that hypoxia can result in the selection of tumour cells with increased resistance to apoptosis (Graeber et al, 1996) . Therefore, as one would expect a strong selection pressure for reduced susceptibility to apoptosis during tumorigenesis, the finding of relatively high rates of apoptotic cell death in high-grade carcinomas seems counter-intuitive. There are several aspects to this paradox: although referred to as 'rate of apoptosis', staining of apoptotic cells and bodies gives little information on the actual rapidity of cell loss by this process, i.e. the duration of the execution phase and the removal and further degradation of apoptotic debris upon phagocytosis. Furthermore, it has been demonstrated that in a model of pancreatic tumorigenesis the transition from premalignant to malignant disease is characterized by a decrease in apoptotic but not proliferative activity (Naik et al, 1996) . Thus, even although in some tumours the observed frequency of apoptosis was high, it is not unthinkable that this frequency would have been even higher in the preinvasive stadium. In addition, as high-grade tumours are often characterized by marked genetic heterogeneity (for example with respect to chromosome numbers) many tumour cells may die as a result of their genetic instability.
Although in vitro experiments clearly showed that Bcl-2 overexpression confers resistance to apoptosis induced by cytotoxic treatment, Bcl-2 did not predict response to chemotherapy in women with node-negative early breast cancer (van Slooten et al, 1996) . However, the strong inverse correlation between Bcl-2 and cell death suggests that Bcl-2 is an important regulator of apoptosis in breast cancer.
The efficacy of Bcl-2 to inhibit cell death depends in part on its binding to other proteins, including other members of the Bcl-2 British Journal of Cancer (1998) 77(5) family: for example binding of Bcl-2 to the proapoptotic protein Bax has been reported to be essential for proper function of Bcl-2 (Yin et al, 1995) and therefore the ratio of these two proteins is believed to be an important determinant of cellular sensitivity to the induction of apoptosis. In breast cancer cells in vitro, increased Bcl-2/Bax ratios reduced the cytotoxicity of taxol (Huang et al, 1997) . Furthermore, loss of Bax expression in vivo was associated with worse prognosis and a positive correlation was found between Bcl-2 and Bax expression (Krajewski et al, 1995) . Hypersensitivity of testicular tumours to drug-induced apoptosis was reported to be associated with a low Bcl-2/Bax ratio (Chresta et al, 1996) .
In the present study, Bax staining (as determined with the use of two different antibodies) did not correlate with Bcl-2 and coexpression of Bax was not associated with changes in the rate of apoptosis. Expression of the antiapoptotic Bcl-2 family member Bcl-X correlated with expression of Bcl-2, but expression of Bcl-X in Bcl-2-negative tumours did not seem to protect against apoptosis, suggesting that in this series suppression of apoptosis depends on Bcl-2 rather than Bcl-X. However, it is important to note that only the two extremes of Bcl-2 expression were studied. Although this approach minimized the impact of the imprecision inherent in TUNEL staining, as a consequence the applicability of these findings to tumours with intermediate levels of Bcl-2 will need to be confirmed. We cannot exclude the possibility that in tumours expressing low to intermediate levels of Bcl-2 coexpression of other Bcl-2 family members has a significant effect on the rate of apoptosis.
Although identified as a proto-oncogene in B-cell lymphomas, Bcl-2 overexpression does not seem to be sufficient to transform normal mammary epithelial cells (Lu et al, 1995) . In vitro and in vivo experiments suggest that: (a) Bcl-2 expression is controlled by oestrogen (Sabourin et al, 1994; Teixeira et al, 1995; Wang and Phang, 1995) and (b) it has been proposed that, by increasing cell survival of breast epithelial cells, Bcl-2 may facilitate differentiation in the mammary gland (Lu et al, 1995) . The present data strongly confirm an inverse relationship between Bcl-2 expression and poor differentiation in breast cancer (Bhargava et al, 1994; Joensuu et al, 1994; Leek et al, 1994; Silvestrini et al, 1994; Lipponen et al, 1995; van Slooten et al, 1996) . This relationship between Bcl-2 and differentiation grade has not only been reported in invasive breast cancer but also in ductal carcinoma in situ (DCIS) . In a previous study, we noted that the majority of Bcl-2-negative invasive tumours were accompanied by Bcl-2-negative DCIS (H-J. van (Lipponen and Aaltomaa, 1994; Aihara et al, 1995; Du et al, 1996; Isacson et al, 1996; Koshida et al, 1996; Shoji et al, 1996) . For instance, in gastric cancer, Bcl-2 expression was positively correlated with a low Al and MI, whereas Bax expression seemed to be correlated with an increased AI and MI. In line with our findings, no correlation was found between Bcl-2/Bax ratios and either AI or MI (Koshida et al, 1996) . In DCIS, apoptotic activity has been reported to be correlated with high grade (Bodis et al, 1996) , indicating a correlation with proliferative activity. It is becoming increasingly clear that certain genes needed for proliferation and transformation play a double role; for example overexpression of c-myc increases the rate of proliferation but at the same time dramatically increases the rate of apoptosis (Evan et al, 1992) . Deregulation of a number of important components in the growth-regulating pathway seem to result not only in the inability to control cell growth, but also apoptosis and post-mitotic differentiation (Field et al, 1996; Kranenburg et al, 1996; Wang et al, 1997) . The strong correlation of cell division and cell death in breast cancers suggests that, similar to c-myc overexpression in vitro, deregulated expression of genes important for proliferation leads to conflicting signals in many cells in vivo, which in turn may induce apoptosis.
Increasing evidence indicates that under certain conditions the induction of apoptosis depends on cell cycle progression and the activity of proteins involved in cell cycle regulation: for example cyclins and cyclin-dependent kinases and their inhibitors (Donaldson et al, 1994; Shi et al, 1994; Shimizu et al, 1995b; Pandey and Wang, 1995; Yao et al, 1996a,b; Zornig and Evan, 1996) . Thus, if cell cycle regulatory genes are linked to the regulation of apoptosis, genes important for apoptosis may in turn be directly linked to the growth-regulating pathway.
Interestingly, it has been reported that Bcl-2 overexpression causes a retardation of mammalian cell proliferation (Pietenpol et al, 1994) . Bomer et al found that whereas Bcl-2 negative cells would die from any point in the cell cycle, Bcl-2 overexpressing cells tended to accumulate in GIG1. Co-expression of Bax reverted both the death protection and inhibition of cell proliferation, whereas a Bcl-2 mutant protein defective in cell death protection did not affect cell proliferation (Borner, 1996) . Similarly, Bcl-2 and its homologues Bcl-X and adenovirus ElB19kD were reported to inhibit cell cycle entry of quiescent NIH3T3 fibroblasts and human colon carcinoma cells (Pietenpol et al, 1994; O'Reilly et al, 1996; Theodorakis et al, 1996) . Overexpression of Bax has been reported to have the opposite effect, increasing the number of cycling thymocytes and accelerating entry into S-phase of cycling T cells (Brady et al, 1996) . These data suggest that Bcl-2 and its homologues contribute to cell survival by diminishing the rate of cell proliferation and possibly allowing cells to undergo terminal differentiation. It is tempting to hypothesize that the preferential expression of Bcl-2 in well-differentiated, slowly proliferating epithelial tumours reflects this connection between Bcl-2 and both cell cycle retardation and differentiation.
Missense mutations in the p53 gene often lead to increased protein stability, resulting in a cellular accumulation of the mutant protein, which can be detected using immunohistochemistry (Sjogren et al, 1996) . In breast cancer, a negative correlation is known to exist between Bcl-2 expression and p53 protein accumulation (Silvestrini et al, 1996) . p53 plays an important role in maintaining genomic stability, regulation of the cell cycle and induction of apoptosis (Ko and Prives, 1996) . In Rb-deficient mice, the loss of p53 function caused resistance to apoptosis (Morgenbesser et al., 1994) , and the loss of both Rb and p53 function has a cooperative effect on tumorigenesis in the mouse . In this study, p53 accumulation seemed to be associated with increased rather then decreased apoptotic activity, suggesting that many of the apoptotic events observed are p53-independent. At present, we are investigating the relationship between p53 mutations, confirmed by DNA mutation analysis, and cell death in a larger series of breast cancers.
